Dr. Lamm is known around world for his pioneering research and clinical trials. He has a particular interest in immunotherapy and chemoprevention, and has authored or co-authored more than 270 publications.

In 1978, while at the University of Texas, Dr. Lamm along with Dr. Pinsky of Memorial Sloan Kettering Cancer Center, was awarded the first NIH-funded contract to evaluate BCG immunotherapy of superficial bladder cancer in a randomized clinical trial. This work resulted in the first controlled trial demonstrating the efficacy of intravesical BCG immunotherapy.

Dr. Lamm continues his research in BCG immunotherapy and chemoprevention, including a clinical trial showing reduced tumor recurrance in BCG patients adminstered megadoses of vitamins

2005 Publications